School of Medicine
Showing 11-20 of 64 Results
-
Gentaro Ikeda
Postdoctoral Research Fellow, Cardiovascular Medicine
BioMy long-term goal is to become a physician scientist and develop innovative diagnostic and therapeutic modalities for patients with cardiovascular disease. Based on my experience as a cardiologist for the past 5 years, I have become aware of major clinical shortcomings, specifically in the current pharmaceutical therapies for myocardial infarction (MI) and chronic heart failure (HF). Some evidence-based drug therapies, including β-blockers, ivabradine, and renin–angiotensin–aldosterone antagonists are difficult to apply to critical patients due to adverse side effects. Drugs that have shown efficacy in basic animal experiments have failed to show significant benefits in clinical trials. To address these problems, I moved to academia to conduct translational research. During my graduate training in the Egashira Lab, I focused on drug delivery systems (DDS) that target mitochondria in animal models of MI. I obtained advanced skills in molecular biology, mitochondrial bioenergetics, and animal surgery. I realized the importance of translational research and the great potential of DDS to overcome many clinical problems. I developed nanoparticle-mediated DDS containing cyclosporine for the treatment of patients with MI. I published a first author paper and received academic awards for my novel science. Since becoming a postdoctoral fellow in the Yang Lab, I have continued to build upon my previous training in translational research. I am currently developing an innovative therapy, namely, extracellular vesicles-mediated mitochondrial transfer for the failing heart.
-
Fumiaki Ikeno
Program Director (U.S) Japan Biodesign, Stanford Biodesign, Medicine - Med/Cardiovascular Medicine
BioProgram Director (U.S) Japan Biodesign, Stanford Biodesign
Cardiovascular Medicine, Stanford University
Dr. Ikeno is a Research Associate, Cardiovascular Medicine, Stanford University. In this role, he is responsible for pre clinical studies including GLP for medical devices and also regenerative medicines for cardiovascular diseases. Currently, he is devoting himself to the international regulatory project between Japan and the United States, also known as "Harmonization by Doing", whose focus is to collaborate with regulatory agencies such as FDA, PMDA/MHLW, academia and industries for improving the regulatory process in the 2 largest medtech markets. Dr. Ikeno also devoted himself to found Japan biodesign program which is a collaborative program with University of Tokyo, Osaka University, Tohoku University, Japan Federation Medical Device Association, Ministry of Education Japan and Stanford biodesign program. Currently, Dr. Ikeno serves as the Program Director (US) for Japan Biodesign. Dr. Ikeno is co-founder and board member of US-Japan MedTech Frontier which is a non-profit cooperate to make a trans-pacific eco-system of medical device between Japan and USA.
After 9 years clinical practice as an interventional cardiologist and Family Doctor in rural areas of Japan, Dr. Ikeno came to Stanford as a Researcher and completed his Biodesign Certificate Program. Being part of the ecosystem in Silicon Valley, Dr. Ikeno participated in more than 200 medtech projects and 50 GLP studies as well as in the analysis of clinical trials for cardiovascular medicine (BARI2D, FAME, ReOPEN etc). His other academic consortium projects include Peripheral Academic Research Consortium, Global Consensus Working Group of Optical Coherence Tomography, and Japan-US consensus document for the treatment of critical limb ischemia.
Over the last decade, Dr. Ikeno has served as an advisor for medical device industries and currently serves as a chief medical officer of an incubation fund specific for medtech (Medventure Partners, Inc, Tokyo) as a spin-off from Innovation Network Corporation of Japan (INCJ) that is the largest government and private partnership fund in Japan. He is also serving as a chair of cardiovascular working group of APAN (Asian Pacific Advanced Network) that contributes the remote education, research activities, and tele-health using a specialized internet network. Dr.Ikeno is also serving as consulting faculty/lecturer roles in several universities in Japan including University of Tokyo, Osaka University, Tsukuba University etc. Dr. Ikeno has authored over 70 peer reviewed publications and textbooks and has been invited to lecture at international medical conferences. Dr. Ikeno is a council member of U.S.- Japan Council which is a non-profit organization by Japanese American. He is serving as a mentor for START-X MED which is an accelerating program for Stanford related entrepreneurs in medical fields.
Contact Information
Falk CVRC CV007
300 Pasteur Drive
Palo Alto, CA 94305-5406 -
Daniel Imler
Clinical Assistant Professor, Emergency Medicine
Clinical Assistant Professor, PediatricsCurrent Research and Scholarly InterestsI am interested in understanding the impact of smart, agile clinical pathways to drive behavior change among providers.
-
Fatih Inci
Affiliate, Rad/Canary Center at Stanford for Cancer Early Detection
BioDr. Fatih Inci is currently working as a Research Scientist at Stanford University School of Medicine, Canary Center at Stanford for Cancer Early Detection. He has been guiding and working with a group of researchers, including postdoctoral fellows, graduate, undergraduate, and high school students, who focus on micro- and nano-technologies for biomedical and bioengineering applications. Dr. Inci received his B.Sc. degree at the Department of Molecular Biology and Genetics in 2007 with magna cum laude honor from Istanbul University (Turkey), and also studied as an Sokrates student at the Department of Biology in University of Groningen (Netherlands) in 2005. He received his Ph.D. degree at the Department of Molecular Biology-Genetics & Biotechnology with summa cum laude honor from Istanbul Technical University (Turkey) in 2013. During his Ph.D. studies, he was also appointed as a visiting scientist at University of New South Wales (Sydney, Australia) and University of Technology Sydney (Australia), as well as working as a research scholar/trainee at Brigham and Women’s Hospital (BWH)-Harvard Medical School, and Harvard-MIT Health Sciences and Technology Division (Boston, MA). Upon the completion of his Ph.D. studies, Dr. Inci worked as a postdoctoral research fellow at BWH-Harvard Medical School (2013-2014) and Stanford University School of Medicine (2014-2015).
Dr. Inci has published his research work in the most prestigious journals, including Proceedings of the National Academy of Sciences of the United States of America (PNAS), ACS Nano, Nature Scientific Reports, Nature Light: Science & Applications, Small, Lab on a chip, Advanced Science, Biomacromolecules, Advanced Drug Delivery Reviews, ACS Chemical Reviews, Biotechnology Advances, Annual Review of Medicine, Materials Today, Trends in Biotechnology. Besides his research publications, he has contributed to the publication of 7 book chapters (including 3 chapters in press) and 3 editorial/perspective papers. He is also editing 3 scientific books in the world's renowned publishers, i.e., Springer Press and World Scientific Publishing Company. His research findings have been presented in national and international conferences, ranging in geography from Barcelona to Osaka, Sydney to Boston, Rio de Janeiro to San Diego and Phoenix to San Francisco. Moreover, he has secured his research findings, technological developments, and scientific discoveries with 6 U.S. patents. Some of them have already been licensed by companies to produce commercial products in the United States, and distributed throughout the world. One such example is his patent in the field of forensics that has been translated into two viable commercial products (CSI-Q and NGDE) produced in the United States by DxNow, Inc.
Dr. Inci’s qualified scientific work has been highlighted and recognized by well-renowned national and international organizations as well as government entities, including National Institute of Health, Nature Medicine, Science AAAS, Popular Science, Newsweek, Boston University, Canary Center-Stanford University, Brigham & Women’s Hospital, A*STAR, Center for Integration of Medicine and Innovative Technology (CIMIT), and Epilepsy Foundation. He has also been awarded with various scholarships and grants from European Molecular Biology Organization-European Science Foundation (EMBO-ESF), American Chemical Society, and Turkey Scientific and Technological Research Society (TUBITAK). He is a professional member at the world’s largest and most prestigious scientific societies, including the American Association for the Advancement of Science (AAAS), Royal Society of Chemistry (RSC), American Association for Cancer Research (AACR), and National Postdoctoral Association (NPA).
